Agree. Not much point beyond perhaps a mail to express your...

Agree. Not much point beyond perhaps a mail to express your disappointment with Paul's "shoddy work" as you say. I communicated my disappointment to him, in the context of John's genuine and somewhat successful efforts on improving the professional guise of the company, board and executive structure along governance and disclosure lines. I am unusual in that I am a large shareholder, like yourself, who does not want to talk to CEO's or Chairs' for many reasons, not least of which me being privvy to something not in the public domain on moral, ethical and legal grounds. They should just have nice clearly defined business strategies via formal ASX disclosure routes for ALL to understand - the point I was making with John and he gets entirely - not obscure casual media chats or individual investor discussions.

I am hopeful ALL shareholders fairly, will get some positive context and clearer clarification of Paul's vague remarks in forthcoming formal disclosures. Its sad but somewhat understandable, that others will have already sold out on the poorly explained revelation from Paul. Its repetitive rhetoric that the executives no doubt allude to themselves at the occasional Crown Casino dinner or investor presentations with with larger potential investors and industry players, but a partnership in Remplir (and accompanying injection of capital) is surely very likely given the context of Striate as others have said above? No way larger US pharma players are unaware or not engaging them given they have explicitly said they are peddling Remplir (and ATI) via paid industry consultants in the US.